
    
      Study AZFD was designed to be integrated with 104-week study AZES to form a Delayed-Start
      study (Study AZES-FD). Study AZES-FD was to be used to test the hypothesis that participants
      originally randomized to receive placebo in the double-blind feeder study AZES and switched
      to LY3314814 at the start of study AZFD did not "catch up" on the Alzheimer's Disease
      Assessment Scale-Cognitive Subscale (ADAS-Cog13) at Week 26 of study AZFD to participants
      originally randomized to receive LY3314814 in the double-blind feeder study.
    
  